1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Gilead's Filing Plans For Magrolimab Depend On Further Data

Company Presents Encouraging Phase Ib Data In TP53-Mutant AML At ASH

 
• By Alaric DeArment

Regardless of future filing based on Phase Ib data, Gilead plugs along with development in TP53-mutant AML, MDS and other cancers.

Leukemia
Gilead presents magrolimab data in acute myeloid leukemia at ASH. • Source: Shutterstock

Updated Phase Ib data on Gilead Sciences, Inc.’ magrolimab in frontline acute myeloid leukemia (AML) have opened the possibility of a filing in a poor-prognosis subset of the disease, though that depends a lot on how the data turn out as they mature and the study enrolls more patients. Regardless, the company is moving ahead on plans to test the drug in a Phase III study in that same subset that will open in early 2021.

The CD47-targeting monoclonal antibody was the centerpiece of Gilead’s $4.9bn acquisition of developer Forty-Seven, which Gilead saw as having “pipeline-in-a-product”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

More from R&D

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.